SBRA vs. TXG

Last updated Apr 1, 2026

Compare and contrast key facts about Sabra Health Care REIT, Inc. (SBRA) and 10x Genomics, Inc. (TXG).

Performance

SBRA vs. TXG - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Sabra Health Care REIT, Inc. (SBRA) and 10x Genomics, Inc. (TXG). The values are adjusted to include any dividend payments, if applicable.

SBRA vs. TXG - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
SBRA Sabra Health Care REIT, Inc.	3.06%	17.02%	31.23%	26.26%	0.38%	-16.16%	-11.33%	-3.19%
TXG 10x Genomics, Inc.	30.17%	13.58%	-74.34%	53.57%	-75.54%	5.20%	85.70%	44.55%

Fundamentals

Market Cap SBRA : $4.86B TXG : $2.70B
EPS SBRA : $0.63 TXG : -$0.35
PS Ratio SBRA : 6.10 TXG : 4.15
PB Ratio SBRA : 1.72 TXG : 3.39
Total Revenue (TTM) SBRA : $774.63M TXG : $642.82M
Gross Profit (TTM) SBRA : $372.04M TXG : $443.88M
EBITDA (TTM) SBRA : $426.24M TXG : -$12.53M

Returns By Period

In the year-to-date period, SBRA achieves a 3.06% return, which is significantly lower than TXG's 30.17% return.

SBRA

• 1D: -1.08%
• 1M: -6.42%
• YTD: 3.06%
• 6M: 6.43%
• 1Y: 17.42%
• 3Y*: 28.26%
• 5Y*: 9.63%
• 10Y*: 8.13%

TXG

• 1D: 7.17%
• 1M: -7.90%
• YTD: 30.17%
• 6M: 81.61%
• 1Y: 143.18%
• 3Y*: -27.53%
• 5Y*: -35.20%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

SBRA vs. TXG — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SBRA

SBRA Risk / Return Rank: 68
SBRA Sharpe Ratio Rank: 71
SBRA Sortino Ratio Rank: 64
SBRA Omega Ratio Rank: 59
SBRA Calmar Ratio Rank: 70
SBRA Martin Ratio Rank: 74

TXG

TXG Risk / Return Rank: 89
TXG Sharpe Ratio Rank: 91
TXG Sortino Ratio Rank: 89
TXG Omega Ratio Rank: 83
TXG Calmar Ratio Rank: 92
TXG Martin Ratio Rank: 90

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SBRA vs. TXG - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Sabra Health Care REIT, Inc. (SBRA) and 10x Genomics, Inc. (TXG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	SBRA	TXG	Difference
Sharpe ratio Return per unit of total volatility	0.84	2.02	-1.18
Sortino ratio Return per unit of downside risk	1.30	2.72	-1.43
Omega ratio Gain probability vs. loss probability	1.15	1.31	-0.16
Calmar ratio Return relative to maximum drawdown	1.39	4.48	-3.09
Martin ratio Return relative to average drawdown	4.21	10.60	-6.39
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

SBRA vs. TXG - Sharpe Ratio Comparison

The current SBRA Sharpe Ratio is 0.84, which is lower than the TXG Sharpe Ratio of 2.02. The chart below compares the historical Sharpe Ratios of SBRA and TXG, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	SBRA	TXG	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.84	2.02	-1.18
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.36	-0.52	+0.88
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.22	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.04	-0.20	+0.23

Correlation

The correlation between SBRA and TXG is 0.18, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

SBRA vs. TXG - Dividend Comparison

SBRA's dividend yield for the trailing twelve months is around 6.24%, while TXG has not paid dividends to shareholders.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
SBRA Sabra Health Care REIT, Inc.	6.24%	6.34%	6.93%	8.41%	9.65%	8.86%	7.77%	8.43%	10.92%	9.22%	6.84%	7.91%
TXG 10x Genomics, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Drawdowns

SBRA vs. TXG - Drawdown Comparison

The maximum SBRA drawdown since its inception was -99.49%, roughly equal to the maximum TXG drawdown of -96.47%. Use the drawdown chart below to compare losses from any high point for SBRA and TXG.

Drawdown Indicators

	SBRA	TXG	Difference
Max Drawdown Largest peak-to-trough decline	-99.49%	-96.47%	-3.02%
Max Drawdown (1Y) Largest decline over 1 year	-12.18%	-28.03%	+15.85%
Max Drawdown (5Y) Largest decline over 5 years	-36.79%	-96.47%	+59.68%
Max Drawdown (10Y) Largest decline over 10 years	-74.93%	—	—
Current Drawdown Current decline from peak	-8.03%	-89.51%	+81.48%
Average Drawdown Average peak-to-trough decline	-37.98%	-58.85%	+20.87%
Ulcer Index Depth and duration of drawdowns from previous peaks	4.03%	11.85%	-7.82%

Volatility

SBRA vs. TXG - Volatility Comparison

The current volatility for Sabra Health Care REIT, Inc. (SBRA) is 5.49%, while 10x Genomics, Inc. (TXG) has a volatility of 22.60%. This indicates that SBRA experiences smaller price fluctuations and is considered to be less risky than TXG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	SBRA	TXG	Difference
Volatility (1M) Calculated over the trailing 1-month period	5.49%	22.60%	-17.11%
Volatility (6M) Calculated over the trailing 6-month period	14.73%	51.34%	-36.61%
Volatility (1Y) Calculated over the trailing 1-year period	20.85%	71.82%	-50.97%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	26.90%	68.47%	-41.57%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	36.51%	66.81%	-30.30%

Financials

SBRA vs. TXG - Profitability Comparison

The chart below illustrates the profitability comparison between Sabra Health Care REIT, Inc. and 10x Genomics, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

SBRA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Sabra Health Care REIT, Inc. reported a gross profit of 0.00 and revenue of 211.90M. Therefore, the gross margin over that period was 0.0%.

TXG - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, 10x Genomics, Inc. reported a gross profit of 113.05M and revenue of 166.03M. Therefore, the gross margin over that period was 68.1%.

SBRA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Sabra Health Care REIT, Inc. reported an operating income of 0.00 and revenue of 211.90M, resulting in an operating margin of 0.0%.

TXG - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, 10x Genomics, Inc. reported an operating income of -19.54M and revenue of 166.03M, resulting in an operating margin of -11.8%.

SBRA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Sabra Health Care REIT, Inc. reported a net income of 26.48M and revenue of 211.90M, resulting in a net margin of 12.5%.

TXG - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, 10x Genomics, Inc. reported a net income of -16.25M and revenue of 166.03M, resulting in a net margin of -9.8%.